Dianthus Therapeutics Stock Rises on Positive Phase 3 Trial Data and Q4 Earnings Report
Dianthus Therapeutics Inc. (NASDAQ:DNTH) saw its shares surge 25.05% in pre-market trading on Monday following significant clinical and financial announcements. The biotechnology company reported its fourth-quarter results, posting a loss of -$1.43 per share on revenues of $280 thousand for the quarter ending December 31, 2025
Early Success in Phase 3 CAPTIVATE Trial
The biggest catalyst behind the stock surge was an early “GO” decision in the Phase 3 CAPTIVATE trial evaluating claseprubart for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The company reached 20 confirmed responders before 40 participants completed the open-label Part A portion of the study. Because the trial surpassed its key benchmark early, Dianthus moved forward ahead of schedule.
Originally, the company expected this decision in the second quarter of 2026. However, the study achieved the milestone sooner after exceeding the required 50% response rate.
As a result, Dianthus now plans to provide top-line guidance for Part B of the CAPTIVATE trial by the end of 2026.
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics, highlighted the significance of the milestone.
“It is truly exciting to be part of a company developing potential best-in-disease therapies for patients suffering from severe autoimmune diseases,” Garcia said.
Full-Year Financial Performance
For full-year 2025, Dianthus reported a net loss of $162.3 million, or $4.20 per share. This result widened compared with a net loss of $85.0 million, or $2.55 per share, in 2024.
The increase largely reflects the company’s expanding research pipeline. In particular, research and development expenses climbed to $145.6 million, up from $83.1 million the previous year.
Higher clinical trial costs and upfront milestone payments tied to the DNTH212 program drove much of that increase.
Strong Cash Position Supports Pipeline
Despite rising expenses, Dianthus maintains a solid financial foundation.
As of December 31, 2025, the company reported $514.4 million in cash, cash equivalents, and investments. According to management, this capital is expected to fund operations into 2028, giving the company significant runway to advance its clinical programs.
Upcoming Clinical Catalysts
Looking ahead, Dianthus plans to launch a Phase 3 registrational trial of claseprubart for generalized Myasthenia Gravis (gMG) in mid-2026.
The company expects to release top-line results from that study in the second half of 2028.
These upcoming milestones could serve as key catalysts as the company works to expand the therapeutic potential of its complement-targeting platform.
About Dianthus Therapeutics
Dianthus Therapeutics Inc. focuses on developing next-generation treatments for severe autoimmune diseases.
Its lead antibody claseprubart (DNTH103) targets the active C1s complement protein, which plays a central role in autoimmune disease pathology. The therapy is engineered with extended half-life, improved potency, and high selectivity, enabling less frequent, self-administered subcutaneous injections.
The company is also developing DNTH212, a bifunctional inhibitor designed to target two complementary mechanisms: Type 1 interferon suppression and B-cell modulation. By combining these mechanisms, the therapy aims to improve clinical outcomes while maintaining convenient subcutaneous administration for patients.
For more investor relations information on Dianthus Therapeutics please visit www.investor.dianthustx.com.
